Logo: Precision Medicine 2020

Hyperindividualized Treatments

Time Topic & Speaker(s)
10:00–10:05 AM Welcome — Isaac Kohane, DBMI Chair, Harvard Medical School
10:05–10:20 AM Opening Remarks — George Daley, Dean, Harvard Medical School
10:20–10:30 AM Introduction — Isaac Kohane
10:30–11:00 AM Keynote Address — Julia Vitarello, Mila’s Miracle Foundation
11:00–11:10 AM BREAK
11:10 AM – 12:00 PM PANEL 1 — How do we scale up? What is the path to industrialization?
  • Amy Abernethy, FDA
  • Arnaub Chatterjee, AcornAI, Medidata
  • Amy DuRoss, Vineti
  • Anupam Jena, Harvard Medical School
  • David Shaywitz (moderator), DBMI, Harvard Medical School
12:00–12:10 PM PAUSE FOR REFLECTION — Brief remarks and 8'46" silence to focus on racial equity and inclusivity
12:10–12:40 PM Fireside Chat – Amy Abernethy, Principal Deputy Commissioner and Acting Chief Information Officer, FDA
12:40–1:00 PM LUNCH BREAK
1:00–1:50 PM PANEL 2 — How do we decide who to treat?
  • Mildred Cho, Stanford
  • George Church, Harvard Medical School
  • Timothy Yu, Boston Children's Hospital
  • Julia Vitarello, Mila’s Miracle Foundation (Q&A portion)
1:50–2:00 PM BREAK
2:00–2:50 PM PANEL 3 — Is there a role for hyperindividualized therapy in common diseases?
  • Pradeep Natarajan, Mass General Hospital
  • Linnea Olson, cancer survivor, patient advocate and activist
  • Stanley Shaw, Harvard Medical School
  • Roman Yelensky, Gritstone Oncology
2:50–3:00 PM BREAK
3:00–3:50 PM PANEL 4 — COVID-19 Therapeutics
  • Galit Alter (moderator), Harvard Medical School
  • Russ Altman, Stanford
  • Albert-Laszlo Barabasi, Northeastern University
  • Paul Farmer, Harvard Medical School
  • Mark Namchuk, Harvard Medical School
3:50–4:00 PM Closing Remarks — Isaac Kohane

Conference sponsored by DBMI, Merck, and Medidata

Logos for Merck and Medidata, sponsors of the 2020 Precision Medicine Conference

What do we mean by “precision medicine”? From the perspective of one of the members of the National Academy of Sciences committee that wrote the report, we mean taking an explicit multidimensional view of patients: not just one data modality such as genomics or environmental exposure. We argue that this perspective allows for more precise matching of humans to disease states (diagnosis), future disease states (prognosis) and appropriate therapies.